How do you manage patients with HER2 positive breast cancer who have progressive CNS metastases after prior exposure to pertuzumab, trastuzumab, TDM1, and lapatinib?  

At our institution we have 3 clinical trials that could be considered but would need more information to match against eligibility criteria.       1. HER2-CLIMB with Tucatanib excludes prior capecitabone. Lapatanib is a relative contraindication depending on duration. This ...